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Abstract
Objective Oxycodone is widely used for the treatment of
cancer pain, but little is known of its pharmacokinetics in
cancer pain patients. The aim of this study was to explore
the relationships between ordinary patient characteristics
and serum concentrations of oxycodone and the ratios
noroxycodone or oxymorphone/oxycodone in cancer
patients.
Methods Four hundred and thirty-nine patients using oral
oxycodone for cancer pain were included. The patients’
characteristics (sex, age, body mass index [BMI], Karnofsky
performance status,“timesince startingopioids”,“oxycodone
total daily dose”, “time from last oxycodone dose”,u s eo f
CYP3A4 inducer/inhibitor, “use of systemic steroids”, “num-
berofmedicationstakeninthelast24h”, glomerularfiltration
rate (GFR) and albumin serum concentrations) influence on
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ratios were explored by multiple regression analyses.
Results Sex, CYP3A4 inducers/inhibitors, total daily dose,
and “time from last oxycodone dose” predicted oxycodone
concentrations. CYP3A4 inducers, total daily dose, and
“number of medications taken in the last 24 h” predicted
the oxymorphone/oxycodone ratio. Total daily dose, “time
from last dose to blood sample”, albumin, sex, CYP3A4
inducers/inhibitors, steroids, BMI and GFR predicted the
noroxycodone/oxycodone ratio.
Conclusion Women had lower oxycodone serum concen-
trations than men. CYP3A4 inducers/inhibitors should be
used with caution as these are predicted to have a significant
impactonoxycodonepharmacokinetics.Othercharacteristics
explained only minor parts of the variability of the outcomes.
Keywords Oxycodone.Metabolites.Ratios.Cancer
population.Drug–drug interactions.Serum concentrations
Introduction
Twenty to forty-five percent of patients with advanced
cancer suffer from moderate to severe pain that requires
treatment with opioids [1–3]. Oxycodone and morphine are
two of the frequently used opioids in cancer pain treatment.
Pharmacokinetic aspects of morphine and metabolites have
been extensively studied and it has been shown that there
are large inter-individual differences in serum concentra-
tions of morphine and metabolites, even after dose
correction [4]. Serum concentrations of morphine and
metabolites are related to morphine dose and route of
administration [4, 5]. While renal function has no influence
on the serum concentrations of morphine, the levels of
metabolites increase with decreasing renal function [5].
The clinical efficacy of oral oxycodone is similar to that
of morphine, but oxycodone is more potent with an
equianalgesic ratio of 1/1.5–2[ 6, 7]. This may partly be
explained by the fact that the oral bioavailability of
oxycodone ranges from 60–87% [8, 9], which is higher
than the 20–40% for morphine [10–12]. Clinical pharma-
cokinetic studies on oxycodone and its major metabolites in
patients are scarce [13–16], especially for cancer pain
patients. Oxycodone is extensively metabolised in the liver,
mainly via CYP3A4 to the inactive metabolite noroxyco-
done (47% of the dose), by 6-keto reduction to the most
likely inactive metabolites, α- and β-oxycodol (8% of the
dose), and via CYP2D6 to the active metabolite oxy-
morphone (11% of the dose), which is mainly found in a
conjugated form in plasma. A third, possibly active
metabolite, noroxymorphone, is formed from noroxyco-
done via CYP2D6, but also to a lesser degree from
oxymorphone via CYP3A4 (Fig. 1)[ 17].
CYP3A4 is involved in the metabolism of about 50% of
all drugs, and does not seem to be under polymorphic
regulation [18, 19]. Inhibition and induction of CYP3A4 is
clinically important as it can cause drug interactions [20,
21]. CYP3A4 activity is subject to a sex difference as
higher activity is reported in women than in men [22, 23].
Furthermore, a 50-fold inter-individual difference in
CYP3A4 expression has been reported [24], and diseases
such as cancer can down-regulate the expression [25, 26].
CYP2D6 is polymorphically regulated and expressed in
four different phenotypes [27, 28]. CYP2D6 is not
inducible, but it may be inhibited by several drugs [29–31].
Thus, an individual’s phenotype can change (phenocopy-
ing) with co-administration of CYP2D6 inhibitory drugs
[32, 33]. A recent study by Samer et al. [34] has shown that
oxycodone and noroxycodone AUCα increased, and oxy-
morphone AUC decreased, after blocking the CYP2D6
metabolic pathways of oxycodone with quinidine in healthy
volunteers. Samer et al. also found decreased noroxycodone
Cmax and increased oxymorphone AUCα after blocking the
CYP3A4 metabolic pathway with ketoconazole. Thus,
oxycodone seems to be vulnerable to drug–drug interactions.
Moreover, Samer’s study indicated that oxymorphone,
despite its modest levels in serum, may contribute to
oxycodone analgesia in humans.
The metabolites of oxycodone are excreted through the
kidneys in free or conjugated form [9, 35]. Peak plasma
concentrations of oxycodone and noroxycodone are higher
in patients with mild-to-moderate hepatic dysfunction or
mild-to-severe renal dysfunction, and oxymorphone con-
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Fig. 1 Oxycodone metabolism. The major metabolic pathway (bold
arrows) of oxycodone is the formation of noroxycodone via CYP3A4
enzymes. Noroxycodone is further metabolised to noroxymorphone
via CYP2D6 enzymes. The minor metabolic pathways (narrow
arrows) are formation of oxymorphone via CYP2D6 enzymes, and
6-keto reduction to α- and β-oxycodol. Oxymorphone is further
metabolised to noroxymorphone via CYP3A4 enzymes
494 Eur J Clin Pharmacol (2011) 67:493–506centrations are lower in patients with impaired hepatic
function [36–38]. Elderly patients may have higher plasma
concentrations of oxycodone than younger patients [39].
BMI (body mass index) is also potentially important to
drug disposition and metabolism. Several studies have
described pharmacokinetic differences for drugs in obese
compared from non-obese subjects [40]. However, insuffi-
cient data for morphine on this topic [41], and no such data
on oxycodone, exist.
The present study is part of the European Pharmacogenetic
Opioid Study (EPOS). Of the 2,294 cancer patients included
in EPOS, 442 used oral oxycodone for their cancer pain. The
primary aim was to examine factors that may affect the
pharmacokinetics of oxycodone. The secondary aim was to
explore factors that influence the most important metabolic
ratios, noroxycodone/oxycodone and oxymorphone/oxyco-
done. Based on the above considerations, it was expected that
the serum concentrations of oxycodone was influenced by
dose, time since last dose to blood sample, sex, age and BMI;
the ratios noroxycodone or oxymorphone to oxycodone by
age, CYP3A4 inhibitors or inducers, or CYP2D6 inhibitors,
number of co-medications and GFR, and the former also by
sex. Moreover, a large inter-individual variability in serum
concentrations and ratios was expected.
Materials and methods
Ethics
This multicentre study was performed according to the
guidelines of the Helsinki declaration and was approved by
the relevant Research Ethics Committee of each study
centre. Before entering the study, participating patients gave
written informed consent.
Subjects
Patients included in EPOS were aged 18 years or more, had
a verified malignant disease, and were treated with regular
oral, subcutaneous, transdermal or intravenous opioids
(morphine, methadone, fentanyl, hydromorphone, buprenor-
phine, ketobemidone or oxycodone) for their cancer pain for
a minimum duration of 3 days. Exclusion criteria were
patients who were not capable of speaking the language used
at the study centre. Patients treated with oral oxycodone were
eligible for the present study.
Assessments and recordings
At the time of inclusion age, sex, weight, height, ethnicity
and cancer diagnosis were registered. The patients’ func-
tional status was assessed by the Karnofsky performance
status [42]. All medications and dosages including opioids
for the previous 24 h, duration of opioid treatment, use of
rescue opioids in last 24 h, route of opioid administration,
and the time interval between last opioid administration and
blood sampling (see below) were recorded. Medications
were categorised as to whether they were CYP3A4 inducers
or inhibitors, or a CYP2D6 inhibitor. The published tables
differ significantly [18, 43]. The web-based table of
Flockhart, for instance, lists glucocorticoids as CYP3A4
inducers, while this group of drugs is notlisted by Wilkinson.
However, the most recent and extensive list was used for this
classification. Moreover, steroids and the other CYP3A4
inducers were categorised as two separate variables. Body
mass index (BMI) was calculated using the international
system of units, BMI=weight (kg)/height
2 (m
2). Renal func-
tion was expressed as calculated glomerular filtration rate
(GFR)/1.73 m
2 body surface [44, 45]. Albumin serum con-
centrations were measured using standard analytical methods.
Blood samples were obtained shortly before drug
administration of the patients’ scheduled oral opioid medi-
cation (trough value). For practical reasons blood samples
from out-patients (n=68) were taken at the time of
examination. Blood samples for opioid analyses in serum
were collected in tubes with no additives and left at ambient
temperatures for 30–60 min before centrifugation at
2,500×g (approximately 3,000 rpm) for 10 min. Serum
was then aliquoted and stored at −80°C prior to analysis.
Statistics
A pre-study formal sample size calculation was not per-
formed since this was an explorative subgroup study within
the larger EPOS study. However, the sample size is larger
than Green’s recommendations (104+k independent varia-
bles) [46], and large enough to detect a medium effect
according to Miles and Shevlin [47].
Descriptive group data are given as median (minimum to
maximum) values. Median oxycodone and metabolites’
serum concentrations and ratios were calculated from the
hospitalised patients (336 slow release, 35 immediate release)
independent of time since last scheduled dose to blood sample
and opioid used as rescue medication. Spearman rank
correlations were used to explore the association between
patient demographic variables and serum concentrations. To
protect against the risk for type I error due to multiple testing,
only variables with p values less than 0.01 were considered
statistically significant, and intended to be included into the
multiple regression analyses. However, variables which did
not meet the p<0.01 criteria, but had shown to be statistically
significant in a similar study on morphine [4] (age), or were
important for determining the progress of cancer in the
individual subject (Karnofsky performance status) were also
included into the multiple regression analyses.
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of oxymorphone/oxycodone and noroxycodone/oxycodone
were log10-transformed to yield normally distributed
residuals. The effect of patient variables on log10-trans-
formed serum concentrations of oxycodone and oxymor-
phone/oxycodone and noroxycodone/oxycodone ratios
were explored by backward stepwise linear regressions,
with the criterion for removal of a variable of p>0.1.
Because data covering all variables for all the patients were
not available (as seen in Table 4 with the different n for the
three regression analyses), the backward stepwise linear
regressions were done manually. p values ≤0.05 (two-sided)
were considered statistically significant in the final model.
Variables included in the multiple regression analyses were
sex, BMI, “time since starting opioids”, “time since last
oxycodone (scheduled or rescue) dose before blood sample”,
“number of medications taken in last 24 h”, “oxycodone
total (scheduled and rescue) daily dose”, “use of CYP3A4
inducer”, “use of CYP3A4 inhibitor”, systemic steroids,
glomerular filtration rate (GFR), albumin serum concentra-
tions (all p<0.01), age and Karnofsky status. “Time since
starting opioid” was calculated from the time the patient
started with any of the opioids fentanyl, morphine, oxy-
codone, methadone, buprenorphine, ketobemidone or hydro-
morphone. Mann–Whitney U test was used to compare
oxycodone total daily dose between men and women, and to
compare serum concentrations of oxycodone, oxymorphone,
and the oxymorphone/oxycodone ratio between users and
non-users of CYP2D6 inhibitors. p values ≤0.05 (two-sided)
were considered statistically significant in the Mann–
Whitney U tests. The statistical software SPSS for Windows
v. 16.0 was used for all statistical analyses.
Materials
Chemicals and reagents
Oxycodone, oxycodone-d6, noroxycodone-HCl, noroxyco-
done-d3 HCl, oxymorphone, oxymorphone-d3 and noroxy-
morphone HCl were obtained from Cerillant (Round Rock,
TX, USA). Acetonitrile (HPLC grade) was obtained from
LabScan and de-ionised water>18 Ω from Purelab Ultra
(ELGA, Bergman, Norway). Formic acid (analytical grade)
was obtained from SDS (Ratstatt, Germany). Plasma for
standard curve calibrations and quality controls was obtained
from St. Olav’s Hospital blood donor centre (Trondheim,
Norway).
Instrumentation and equipment
The liquid chromatography system used was an Agilent
1100 series HPLC system fitted with a G1311A quaternary
pump, a G1322A degasser and a G1313A autosampler, all
from Agilent Technologies (Matriks, Norway). Column
heating was performed with a Universal-Thermostat column
oven from Mikrolab (Aarhus, Denmark). The Zorbax SB-
C18 (2.1×150 mm, 5 μm) column and the Zorbax SB-C8
pre-column (4.6×12.5 mm, 5 μm) were purchased from
Agilent Technologies . The MS-MS system consisted of an
API 4000 QTrap and API 5000 triple quadruple mass
spectrometer from Sciex Instruments (Applied Biosystems,
Streetville, ON, Canada).
Serum concentrations
Edwards and Smith’s[ 48] protein precipitation method,
with the following modifications, was applied to extract
oxycodone and its metabolites oxycodone, noroxycodone,
oxymorphone and noroxymorphone from 0.2 ml serum.
After addition of internal standards (oxycodone-d6,
noroxycodone-d3 and oxymorphone-d3,2 0μl of a 50 ng/
ml solution) to the sample, proteins were precipitated by
adding acetonitrile (0.9 ml). The sample was then whirl-
mixed and left in the fridge for 30–60 min. The sample was
centrifuged at 12,000×g for 10 min, supernatant was then
frozen at −80°C and evaporated in a vacuum concentrator
(MAXI dry lyo, Heto Holten A/S, Allerø, Denmark) until
freeze dried (2–3 h). A solution of 50 μl containing 20%
acetonitrile with 0.1% formic acid and 80% water with
1.0% formic acid was added, the sample whirlmixed and
centrifuged at 12,000×g for 10 min. The supernatant was
transferred into LCMS vial and capped. Oxymorphone-d3
was used as an internal standard for noroxymorphone.
An LC-MS/MS method validated in accordance with
Dadgar [49] and Shah [50] was used for identification and
quantitative analysis of drug and metabolites in the
extracted samples. Analytical separation was performed
with a column oven at 40°C using a Zorbax SB-C18
column with a Zorbax SB-C8 pre-column at a flow rate of
0.2 ml/min and a gradient elution. The gradient was
initiated with 20% acetonitrile with 0.1% formic acid and
80% water with 1.0% formic acid (5.0 min), and then with
a stepwise increase to 100% (5.20 min) acetonitrile with
0.1% formic acid. After 7.0 min the acetonitrile concentra-
tion was decreased to 20% (7.2 min) and was kept constant
until end of the run (14.0 min). Injection volume was 10 μl.
The MS/MS system was operated with multiple ion moni-
toring (MRM), with the following ions monitored: 316.1→
241.1 for oxycodone, 302.1→227.2 for noroxycodone and
oxymorphone, and 288.0→213.0 for noroxymorphone.
The standard curve ranges were oxycodone 0.32–16 nM
(0.1–500ng/ml),oxymorphone0.07–166nM(0.02–50ng/ml),
noroxycodone 0.17–3,314 nM (0.05–1,000 ng/ml) and
noroxymorphone 0.17–696 nM (0.05–200 ng/ml). The
calibration curves were obtained from linear or quadratic
regression with 1/x or 1/x
2 weighing of the analyte-to-
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analyte concentration. Correlation coefficients were r>0.998
for all standard curves. Coefficients of variation (intra- and
inter-day) for each analyte were 16.5 and 8.3% (0.32 nM), 4.4
and 4.0% (1.6 nM), 6.0 and 3.9% (31.7 nM), 4.5 and 3.7%
(634.2 nM), and 5.5 and 4.8% (1,268.4 nM) for oxycodone;
8.8 and 6.7% (0.8 nM), 5.8 and 3.4% (3.6 nM), 4.4 and 3.9%
(76.2 nM), 10.8 and 5.6% (1,325.6 nM), and 6.5 and 5.8%
(2,651.2 nM) for noroxycodone; 10.0 and 7.5% (0.2 nM), 9.7
a n d7 . 1 %( 0 . 3n M ) ,8 . 9a n d4 . 4 %( 3 . 3n M ) ,6 . 0a n d3 . 6 %
(66.4 nM), and 7.0 and 3.8% (132.7 nM) for oxymorphone;
and 10.0 and 7.1% (0.7 nM), 9.2 and 5.7% (0.9 nM), 6.9
and 6.5 (12.2 nM), 6.4 and 5.5% (208.8 nM), and 14.8 and
7.7% (471.7 nM) for noroxymorphone. The limits of
quantification were 0.32 nM (0.1 ng/ml) for oxycodone,
0.07 nM (0.02 ng/ml) for oxymorphone, and 0.17 nM
(0.05 ng/ml) for noroxycodone and noroxymorphone.
Results
Patients
The EPOS included 2,294 cancer patients from 17 centres in
11 European countries, with 461 patients (98% Caucasians)
treated withoxycodone.Twenty-twopatients wereexcluded;
17 because they were treated with intravenous (5) or
subcutaneous (12), oxycodone, 2 because of lack of a blood
sample and 3 because neither oxycodone nor metabolites
could be detected in serum. Thus, 439 patients using oral
oxycodone (394 slow release, 48 immediate release) were
included for analysis (Fig. 2).
The patients’ demographic data are shown in Table 1.
Their median age was 63 years, and 56% were men.
Median Karnofsky performance score was 70%. Two-thirds
had lung, breast, prostate or GI cancer. Eighty-two percent
of the patients had metastases. Thirteen percent (n=59) of
the participants were suffering from renal disease/dysfunc-
tion (GFR<60 ml/min per 1.73 m
2 body surface), while
58% (n=253) had albumin serum concentrations below the
normal range (35–55 g/L). Forty-four percent of the
patients used rescue opioid doses (90% used oxycodone).
One-hundred and sixty-nine patients used oral immediate
release, 6 subcutaneous and 1 intravenous oxycodone as
rescue medication. Nineteen patients used opioids other
than oxycodone as rescue medication.
Median time from last opioid dose to blood sample was
10 (0.1–17) h.
Virtually all patients (99%) used other drugs in addition
to opioids, and 12 used herbal medications. Patients had
taken a median of 6 non-opioid drugs during the previous
24 h. The most frequently co-administered classes of drugs
were laxatives (57%), histamine 2 receptor antagonists
(57%), paracetamol (53%), systemic steroids (48%) and
antiemetics (37%). Thirty-five patients used one or more
medications known to inhibit CYP2D6 such as haloperidol
(28), fluoxetine (2) or paroxetine (1), hydroxyzine (2),
doxepine (1), chlorpromazine (1) and amidarone (1).
Fifteen used the CYP3A4 inhibitor fluconazole. Other
CYP3A4 inhibitors used were clarithromycin (2), verapamil
(3), nelfinavir (1), itraconazole (1) and diltiazem (1). Three
patients used the CYP3A4 inducer carbamazepine and one
used phenobarbital [18, 43]. Two-hundred and twelve used
systemic steroids that according to Flockhart [43]a r e
CYP3A4 inducers.
The median oxycodone scheduled daily dose was 60
(range 10–760) mg. The median oxycodone rescue dose
was 20 (range 5–360) mg, and median oxycodone total
daily dose (sum of scheduled and rescue) was 80 (range
10–960) mg. The 95% CIs for the mean oxycodone
scheduled daily dose were 87–109 mg/24 h, 29–42 mg/
24 h for rescue and 102–128 mg/24 h total daily dose
(Table 2). The resulting serum concentrations of oxycodone
and metabolites and their ratios displayed wide ranges, even
after dose correction (Table 3). Oxycodone serum concen-
tration varied from 0 to 1,890 (median 100) nM, while
those of noroxycodone, oxymorphone and noroxymor-
phone varied from 0 to 4,858 (median 106), 0–27 (median
1.5) and 0–509 (median 17) nM respectively. The 95% CIs
for the uncorrected mean values were 139–183 nM for
Patients included in 
EPOS  
(n = 2294)
Treated  
with oxycodone 
(n = 461)
Oral administration 
(n = 444) 
Included in blood 
analyses 
(n = 442)
Other opioids 
(n = 1833) 
Subcutaneous (n = 12) 
Intravenous (n = 5) 
Blood sample missing 
(n = 2) 
No serum 
concentrations detected  
(n = 3)
Included in the statistical 
analyses 
(n = 439)
Fig. 2 Study flow sheet. The European Pharmacogenetic Opioid
Study included 2,294 cancer patients of whom 461 were treated with
oxycodone. Four hundred and forty-four used oral oxycodone, 439
were included in the analyses
Eur J Clin Pharmacol (2011) 67:493–506 497oxycodone, 174–245 nM for noroxycodone, 2.3–3.0 nM
for oxymorphone and 26––34 nM for noroxymorphone.
The noroxycodone/oxycodone and oxymorphone/oxy-
codone ratios varied from 0.1 to 24.4 (median 1.1) and
from 0.00032 to 0.21 (median 0.02) respectively (Table 3).
The 95% CI for the mean was 1.4–1.8 nM and 0.020–
0.025 nM respectively. The distributions of these ratios are
shown in Fig. 3 as a histogram and P-P plots. Four patients
lacked a noroxycodone/oxycodone ratio, because there was
no detectable oxycodone and noroxycodone (n=2), no
detectable oxycodone (n=1) and no detectable noroxyco-
done (n=1). Fifteen patients had an oxymorphone/oxy-
codone ratio of zero, 12 because oxymorphone was not
detected, and 3 because oxycodone was not found. These
patients were given a fictive low serum concentration value
(assay detection limit × 0.5) and were included in the
distribution (Fig. 3).
Relations between serum concentrations and ratios
and the patient-related variables
Serumconcentrationsofoxycodone(rs=0.71), oxymorphone
(rs=0.56), noroxycodone (rs = 0.75) and noroxymorphone
(rs=0.68) correlated (p<0.001 for all) with oxycodone total
daily dosage (Fig. 4, shown only for oxycodone). Serum
concentrations of noroxycodone (rs, females=0.79, rs, males=
0.76), oxymorphone (rs, females = 0.73, rs, males = 0.66) and
noroxymorphone (rs, females=0.64, rs, males=0.59) were
closely associated (p<0.001 for all) with oxycodone serum
concentrations for both men and women. At a given level of
oxycodone, women have higher corresponding metabolite
serum concentrations (Fig. 5). Correlations between oxy-
codone daily dose and the ratios oxymorphone/oxycodone
(rs, females=−0.32, rs, males=−0.33) and noroxycodone/
oxycodone (rs, females=−0.33, rs, males=−0.13) were low
(p<0.001 for all; data not shown). Moreover, there was no
correlation between serum concentration and GFR (data not
shown).
Table 4 shows the results from the multiple linear
regression analysis with the outcomes oxycodone serum
concentrations, the oxymorphone/oxycodone ratio and the
noroxycodone/oxycodone ratio, respectively.
“Oxycodone total daily dose”, “time from last oxy-
codone dose (scheduled or rescue) to blood sample” (p≤
0.001 for both), “CYP3A4 inducer” (p=0.001), “CYP3A4
inhibitor (p=0.044) and sex (p=0.010) were associated
with oxycodone serum concentrations. Together these
factors explain 35% (R
2=0.35) of the observed variation.
Total daily dose had the largest standardised coefficient,
and was therefore the most prominent of all variables. Total
daily dose and use of CYP3A4 inhibitors displayed positive
association. This means that increasing the dose and
Table 1 Demographics and characteristics of the 439 patients
included in the analyses
Demographic/characteristic Statistic
Men/women 247/192
a
Age (years) 63 (18–91)
b
BMI (kg/m
2) 24 (14–41)
b
Height (cm) 171 (148–199)
b
Karnofsky performance status score (%) 70 (20–90)
b
Time since cancer diagnosis (months) 18 (0–286)
b
Time since start opioids (months) 1 (0–97)
b
Time since last oxycodone dose before
blood sample (hours)
10 (0.1–17)
b
Number of medications in addition to
oxycodone
6( 0 –17)
b
Glomerular filtration rate (GFR)
(ml/min/1.73 m
2)
96 (24–261)
b
Serum albumin (g/L) 33 (10–91)
b
Oxycodone rescue medication (yes/no) 176/263
a
Oral immediate release oxycodone 169
a
Subcutanous oxycodone 6
a
Intravenous oxycodone 1
a
Other than oxycodone 19
a
Cancer diagnosis
Gastrointestinal (inclusive pancreas, liver) 19.8
c
Prostate 17.5
c
Lung (inclusive mesothelioma) 16.6
c
Breast 14.8
c
Female reproductive organs 7.5
c
Haematological 6.6
c
Other urological 6.4
c
Head and neck 2.5
c
Skin 2.1
c
Sarcoma 2.0
c
Other cancer diagnoses 5.7
c
More than one diagnosis 4.3
c
Unknown origin 2.7
c
Metastases (yes/no) 359/55
a
Bone 49.8
c
Liver 22.2
c
Lung 19.0
c
CNS 5.2
c
Other 33.3
c
More than one 47.2
c
Pain category
Somatic pain 56.9
c
Mixed pain 27.8
c
Visceral pain 11.6
c
Neuropathic pain 3.6
c
aNumber
bMedian (minimum to maximum)
cPercentage (%)
498 Eur J Clin Pharmacol (2011) 67:493–506inhibition of the CYP3A4 metabolic pathway favour
increased oxycodone serum concentrations. Men were
predicted to have about 30% higher oxycodone serum
concentrations than women. “CYP3A4 inducer” and “time
from last oxycodone dose (scheduled or rescue) to blood
sample” displayed negative associations. Thus, longer time
between tablet intake and blood sampling and use of a
CYP3A4 inducer as concomitant medication decrease
oxycodone serum concentrations. Users of CYP3A4 induc-
er drugs are predicted to have 84% (see notes to Table 4 for
calculation) lower serum concentrations of oxycodone than
those without the CYP3A4 inducer drug. Users of CYP3A4
inhibitors are predicted to have 60% higher oxycodone
serum concentrations than non-users.
The variables “oxycodone total daily dose” (p=0.004),
“number of medications except opioids taken in the last
24 h (p=0.003) and “CYP3A4 inducer” (p=0.010), only
explained 5% (R
2=0.05) of the observed variation in
oxymorphone/oxycodone ratio. The variables total daily
dose and number of medications were negatively associated
with this ratio. Thus, an increase in total daily dose or
“number of medications” decreases the oxymorphone/oxy-
codone ratio. Users of CYP3A4 inducers are predicted to
have a three times higher oxymorphone/oxycodone ratio,
than non-CYP3A4 users. All variables had a similar impact
on the explained variation (see their standardised coeffi-
cients, Table 4).
Except for age, Karnofsky performance status, “time
since starting opioids” and “number of medications”, the
ratio noroxycodone/oxycodone was associated with all
examined variables, with oxycodone total daily dose being
the most important. However, these variables together only
explained 19% (R
2=0.19) of the variation. Use of CYP3A4
inhibitor (p=0.000), BMI (p=0.019) and glomerular filtra-
tion rate (p=0.002) showed a negative association. Men are
predicted to have 22% (see notes to Table 4 for calculation)
lower noroxycodone/oxycodone ratio than women (p=
0.002), and use of a CYP3A4 inhibitor is predicted to give
a 49% reduction in ratio compared with non-users of
CYP3A4 inhibitors. An increase in BMI or glomerular
filtration rate will decrease the ratio. Users of CYP3A4
inducers are predicted to have about 4 times higher
noroxycodone/oxycodone ratio. Users of systemic steroids
are predicted to have 15% lower ratio than those not using
Table 3 Uncorrected serum concentrations (nM) of oxycodone,
noroxycodone, oxymorphone, noroxymorphone and dose-corrected
(nM × 100 mg 24 h
−1/dose 24 h
−1) serum concentrations, and ratios
noroxycodone/oxycodone and oxymorphone/oxycodone given as
median, 25th and 75th percentiles, minimum to maximum values,
mean and 95% CI for mean for the hospitalised patients
Serum concentrations Median 25th percentile 75th percentile Minimum to maximum Mean 95% CI
Low High
Oxycodone
a 97 43 201 0–1,890 161 139 183
Oxycodone
b 144 90 225 0–1,294 186 170 203
Noroxycodone
a 101 44 211 0–3,571 209 174 245
Noroxycodone
b 161 103 261 0–3,032 212 188 235
Oxymorphone
a 1.5 0.7 3.2 0–25 2.6 2.3 3.0
Oxymorphone
b 2.2 1.2 4.2 0–34 3.4 3.0 3.8
Noroxymorphone
a 17 8 39 0–509 30 26 34
Noroxymorphone
b 29 18 44 0–360 34 31 38
Ratio noroxycodone/oxycodone
a 1.1 0.7 1.9 0.1–24.4 1.6 1.4 1.8
Ratio oxymorphone/oxycodone
a 0.02 0.01 0.03 0.00032–0.21 0.02 0.02 0.02
aUncorrected serum concentrations
bDose-corrected serum concentrations
Table 2 Oxycodone scheduled daily dose, total daily dose of oxycodone rescue medication and total daily oxycodone (scheduled and rescue; mg/
24 h) given as median, 25th and 75th percentile, minimum to maximum values, mean and 95% CI for the hospitalised patients
Oxycodone daily dose: Median 25th percentile 75th percentile Minimum to maximum Mean 95% CI
Low High
Scheduled 60 40 120 10–760 98 87 109
Rescue 20 10 40 5–360 35 29 42
Total (scheduled and rescue) 80 40 125 10–960 115 102 128
Eur J Clin Pharmacol (2011) 67:493–506 499steroids. The remaining variables predict increased norox-
ycodone/oxycodone ratio.
Forty-seven of the 439 patients used immediate-release
oxycodone every 4–6 h, while the remaining 392 were
using controlled-release oxycodone approximately every
12 h. All the regression analyses were also performed
without the immediate release users to determine whether
oxycodone formulation affected the data. The outcome of
this analysis did not differ from the outcome of the complete
analysis. Serum concentrations of oxycodone (p=0.49),
oxymorphone (p=0.12) and the ratio oxymorphone/oxy-
codone (p=0.15) did not differ between users and non-users
of CYP2D6 inhibitors.
The following variables included in the analyses did not
explain variability in any of the outcomes: age, Karnofsky
performance status and “time since starting opioids”.
Finally, other variables that were explored, but not
included in the multiple regression analyses were; “use of
steroids”, “use of dexamethasone”, “use of CYP2D6
inhibitor”, “having liver metastases” and “time since
starting opioids in months”.
Discussion
The focus of this study was to examine if common
clinically observed factors could predict variation in oxy-
codone serum concentrations and the metabolite to oxy-
codone ratios in cancer patients. It was shown that
oxycodone total daily dose, use of CYP3A4 inducers/
inhibitors, sex and the time from the last oxycodone dose to
blood sample explained variations in serum concentrations
Fig. 3 a Log10-transformed distributions of CYP3A4-dependent
noroxycodone/oxycodone ratio and b the CYP2D6-dependent
oxymorphone/oxycodone ratio. Histograms on the left and P-P
plots (expected cumulative probability vs observed cumulative
probability) on the right
500 Eur J Clin Pharmacol (2011) 67:493–506of oxycodone. It was also observed that the ratios for the
serum concentrations of the metabolites noroxycodone and
oxymorphone to oxycodone were influenced by the use of
CYP3A4 inducer drugs and oxycodone total daily dose.
The number of medications except opioids taken in the last
24 h was the only additional factor for the oxymorphone/
oxycodone ratio. The noroxycodone/oxycodone ratio was
in addition influenced by sex, use of CYP3A4 inhibitor,
BMI, GFR, albumin and time from last dose to blood
sample. However, the regression models could only explain
minor parts of the variability of serum concentration and
ratios of oxycodone and metabolites.
The wide concentration ranges of oxycodone and
metabolite serum concentrations observed were expected,
not least due to the wide dose range observed in this
sample. These observations agree with the studies that
showed large individual differences in serum concentrations
even after dose correction for patients receiving morphine
[4, 51–53]. Total daily dose correlated highly with the
variable that best explained the variability of oxycodone
serum concentrations. Rescue medication is frequently used
by cancer pain patients. In this sample 44% of the patients
used rescue medication, the majority oxycodone (90%).
The use of rescue medication may confound data interpre-
tation; however, this was corrected for by using the two
variables “time since last dose” and “total daily dose” in the
regression analyses.
The observed sex differences related to dose and serum
concentrations of oxycodone are interesting. First, men
used higher total daily doses than women (median 80 mg/
24 h vs 70 mg/24 h, p=0.03). It is unlikely that the higher
body weight of men accounts for this difference as dosing
for cancer pain is not based on weight, but titration to the
desired effect. It is more likely that it reflects that men may
be less sensitive than women to opioids, and therefore may
require higher doses to relieve similar levels of pain [54, 55].
There are no published data on sex differences in oxycodone
dosage requirements, although studies with morphine have
shown that men need at least 30–40% more morphine than
women for pain relief [54]. This agrees with the finding in
this study where men had higher serum concentrations of
oxycodone than women (about 30%, as calculated from the
regression analysis). Since sex and daily dose are indepen-
dent variables in the analyses, sex as a factor in itself also
contributes to the difference in oxycodone serum concen-
tration. This may well be explained by a higher metabolic
capacity in women as discussed below.
Formation of noroxycodone by CYP3A4 is the major
elimination pathway of oxycodone [35]. The observation
that men are predicted to have a 31% lower noroxycodone/
oxycodone ratio than women may fit with higher CYP3A4
activity in women. Thus, the higher oxycodone serum
concentrations in men may be explained by a lower activity
of CYP3A4 compared with women. This is supported by a
number of in vitro studies [56–59]. Also, in vivo studies
have shown that women seem to exhibit faster clearance
of CYP3A4-metabolising drugs [22, 23, 60], although
some studies have failed to detect this clearance difference
[61, 62].
A secondary outcome was to assess whether clinical
variables can be used to predict the metabolite to parent
drug ratios, assuming that this exploration of ratios could
shed light on the elimination pathways of oxycodone. It
was unexpected that oxycodone total daily dose explained
the variability of metabolite to parent drug ratios. We would
expect both ratios to remain constant for an individual,
assuming that the elimination pathways of oxycodone
followed first-order kinetics. Thus, this finding may indicate
that all processes involved in these ratios might not obey
first-order kinetics.
Oxymorphone is formed from oxycodone mainly by
CYP2D6 enzymes and excreted mainly as an oxymorphone-
3-glucuronide conjugate [31]. CYP2D6 is under poly-
morphic regulation. The oxymorphone/oxycodone ratio
may therefore be subject to a polymodal distribution. While
the distribution of the noroxycodone/oxycodone ratio was
normal as expected for a potential phenotypic expression of
CYP3A4, this was not obvious for the oxymorphone/
oxycodone ratio. Both histogram and P-P plot showed
indices of multimodal distribution, although no clear
bimodality could be seen. One reason for this may be that
oxymorphone is further metabolised by UDP-glucuronosyl-
transferase to oxymorphone-3-glucuronide and variability in
this metabolic pathway may influence the distribution of the
oxymorphone/oxycodone ratio. Also, factors other than
genotype may explain the variability of this ratio as
discussed below.
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Fig. 4 Spearman rank correlation (rs) between oxycodone total daily
dose (mg/24
−1) and serum concentrations of oxycodone (nM; rs=0.71,
p<0.001) for the hospitalised patients
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by a number of other drugs [18, 31]. Most of the co-
administered drugs used in our study are not known to inhibit
CYP2D6,asonly8%ofthepatients(n=35) were treated with
known CYP2D6 inhibitors. Use of CYP2D6 inhibitors did
not influence the oxymorphone/oxycodone ratio. Moreover,
the low number of known CYP2D6 inhibitors observed in
this large sample of patients recruited from several centres
indicates that the use of these drugs is infrequently
indicated in cancer pain patients. However, it remains the
case that increasing numbers of co-administered drugs
reduce the ratio pf oxymorphone to oxycodone.
Many factors seem to influence the noroxycodone/
oxycodone ratio. Some of the factors, such as sex, GFR,
use of CYP3A4 inducers/inhibitors and “time from last
oxycodone (scheduled or rescue) dose to blood sample” can
probably be explained by common pharmacokinetic knowl-
edge. GFR is an independent variable predicting a
noroxycodone/oxycodone ratio rise when GFR decreases.
This rise may possibly be explained by reduced renal
clearance, causing a relative accumulation of noroxyco-
done, which is mainly excreted through the kidneys. In fact,
the AUC ratio for noroxycodone/oxycodone was three
times higher in renal failure patients compared with subjects
with normal renal function after intravenous administration
of oxycodone [37]. Thus, reduced renal function may
change several aspects of the overall pharmacokinetics of
oxycodone.
Two of the factors that influence the noroxycodone/
oxycodone ratio, BMI and albumin, are difficult to explain.
Serum concentrations of oxycodone have previously shown
to be associated with albumin [63]. This could potentially
have explainedthe ratio, although albumin didnot contribute
to the variability of oxycodone serum concentrations itself.
The overall median noroxycodone/oxycodone ratios in
this study in cancer patients was in accordance with results
from previous studies [9, 35, 39]. The oxymorphone/
oxycodone ratio was also in line with other studies, and
rs, female= 0.79, p < 0.001
rs, male   = 0.76, p < 0.001
rs, female= 0.73, p < 0.001
rs, male   = 0.66, p < 0.001
rs, female= 0.64, p < 0.001
rs, male   = 0.59, p < 0.001
Fig. 5 a–c Spearman rank correlations (rs) for men (rs, males) and women (rs, females) between oxycodone and noroxycodone, oxymorphone and
noroxymorphone serum concentrations (rs=0.59–0.79, p<0.001) for the hospitalised patients
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compared with its parent substance in this group. A previous
study has claimed that the levels of oxymorphone in the
brain relative to the parent drug oxycodone [35] is very low.
However, recent experimental studies in humans have
documented that oxymorphone contributes to analgesia
[64, 65]. Although not shown, this may therefore also be
the case in cancer patients.
Concomitant medication with CYP3A4 inhibitors, as
expected, reduced the CYP3A4-mediated noroxycodone/
oxycodone ratio. The use of CYP3A4 inducers on the other
hand, influenced all three examined outcomes. The ob-
served changes in the ratios comply with an increased
CYP3A4 activity, thus lowering oxycodone concentration
and increasing those of noroxycodone. However, except for
systemic steroids, CYP3A4 inducers were used by only 4
patients and these 4 alone had a remarkable influence on
both ratios and the oxycodone serum concentrations. Thus,
potential CYP3A4 drug–drug interactions, especially with
the use of CYP3A4 inducers, are also important to consider
when administering oxycodone in cancer patients.
We recognise that compared with experimental pharmaco-
kineticstudiesinvolunteers(healthyorwithcancer)thisstudy
is subject to a number of confounding factors. However, this
multicentre cross-sectional study resulted in a patient popu-
lation representative of the heterogeneity of cancer patients
Table 4 Multiple linear regression models with factors predicting the serum concentrations of oxycodone and the ratios oxymorphone/oxycodone
and noroxycodone/oxycodone
Factors
a associated with Unstandardised coefficients
b Standardised
coefficients
95% confidence interval
for B
B Standard
error
Beta Significance Lower
bound
Upper
bound
Oxycodone (n=433; R
2=0.35)
b
Oxycodone total daily dose 0.002 0.0002 0.491 0.000 0.002 0.002
CYP3A4 inducer
c −0.786 0.233 −0.131 0.001 −1.242 −0.327
CYP3A4 inhibitor
c 0.204 0.101 0.078 0.044 0.005 0.403
Sex
d 0.113 0.045 0.098 0.012 0.025 0.201
Time from last oxycodone dose to blood sample −0.027 0.006 −0.189 0.000 −0.038 −0.016
Ratio oxymorphone/oxycodone (n=438; R
2= 0.05)
b
Oxycodone total daily dose −0.0004 0.0001 −0.136 0.004 −0.0007 −0.0001
CYP3A4 inducer
c 0.607 0.234 0.122 0.010 0.147 1.067
Number of medications (excluding opioids) taken
in the last 24 h
−0.024 0.008 −0.140 0.003 −0.039 −0.008
Ratio noroxycodone/oxycodone (n=396; R
2=0.19)
b
Oxycodone total daily dose 0.001 0.0001 0.231 0.000 0.0003 0.001
Time from last oxycodone dose to blood sample 0.012 0.004 0.147 0.002 0.004 0.020
Albumin 0.006 0.002 0.132 0.005 0.002 0.010
Sex
d −0.110 0.033 −0.160 0.001 −0.175 −0.045
CYP3A4 inducer
c 0.602 0.183 0.153 0.001 0.242 0.962
CYP3A4 inhibitor
c −0.294 0.068 −0.197 0.000 −0.427 −0.160
Systemic steroids
c,e −0.070 0.032 −0.102 0.028 −0.132 −0.008
BMI −0.009 0.004 −0.109 0.019 −0.017 −0.001
Glomerular filtration rate −0.001 0.0004 −0.161 0.001 −0.002 −0.0005
aIndependent variables in all analyses were age (years), sex, BMI (kgm
−2), Karnofsky performance status (%), time from last oxycodone dose to
sample (h), oxycodone total daily dose (mg/24 h), time since starting opioids (months), number of concomitant medications in the last 24 h, use of
CYP3A4 inhibitor (yes/no), use of CYP3A4 inducer (yes/no), glomerular filtration rate (mlmin
−1 1.73 m
−2) and albumin (gl
−1) serum
concentrations
bCoefficients are in log 10 form (e.g. 10
0.002 × oxycodone daily dose)
cYes=1, no=0 (user of systemic steroids yes: 10
−0.070 × 1, NO: 10
−0.070 × 0)
dMen=1, women =0 (male oxycodone serum concentration: 10
0.113 × 1, women: 10
0.113 × 0, noroxycodone/oxycodone ratio men: 10
−0.110 × 1,
women: 10
−0.110 × 0)
eThe patients in the CYP3A4 inducer (n=4) group also used systemic steroids
Eur J Clin Pharmacol (2011) 67:493–506 503physicians are faced with in day-to-day clinical work.
Moreover, this study is unique with its large sample size
where clinical characteristics and extensive data on the serum
concentrations of oxycodone and its major metabolites are
combined. The use of multiple regression analysis made it
possible to control for differences between the patients with
respect to common clinical variables. Thus, despite the
heterogeneity of the sample, a number of plausible variables
related to the variability of the outcomes were also confirmed
in cancer patients. The explained variability of the dependent
variables was low in these regression analyses, especially for
the ratios, which comply with those of a previous publication
[4]. Plausible reasons for this are the fact that cancer patients
are a very heterogeneous group of patients; the origin and
progression of their cancer differ, their metastatic status
differs, their metabolic status differs, and of course there are
genetic and perception differences.
Conclusions
Sex differences related to opioids and metabolism may also
be true in a cancer population. Drug–drug interactions
related to CYP2D6 are probably of little clinical signifi-
cance; however, use of CYP3A4 inducers or inhibitors
should be carefully monitored, as these might significantly
influence the serum concentrations, which may possibly
change the effects of oxycodone. Pharmacokinetics in
special populations, such as patients with renal failure and
obesity, should be studied further. Finally, the variables,
including daily dose, explained one third of the variability
of oxycodone serum concentrations and only minor parts of
the variability of the ratios in this population.
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